Status Epilepticus: Updated Treatment Algorithm and Refractory Management
Definition and Time-Based Framework
The Neurocritical Care Society and ILAE define status epilepticus (SE) as continuous seizure activity lasting 5 or more minutes or recurrent seizures without return to baseline. The operational framework identifies treatment timepoints: T1 (5 minutes, administer first-line benzodiazepine), T2 (20 minutes, second-line antiseizure medication if benzodiazepine fails), and T3 (40 minutes, refractory SE requiring anesthetic infusion). Each minute of delayed treatment reduces the probability of seizure termination: benzodiazepines are effective in 80% of patients when administered within 5 minutes but only 40% when delayed beyond 30 minutes.
First-Line Therapy: Benzodiazepines
IV lorazepam 0.1 mg/kg (max 4 mg per dose, may repeat once) is the first-line treatment in the hospital setting, with seizure termination rates of 65% within 10 minutes (RAMPART and VA Cooperative Study). IM midazolam 10 mg (weight above 40 kg) is preferred in the prehospital setting, based on the RAMPART trial showing noninferiority to IV lorazepam (73.4% versus 63.4% seizure cessation by ED arrival, p<0.001 for noninferiority). Intranasal midazolam (5 mg per nostril), buccal midazolam (10 mg), and rectal diazepam (0.2 mg/kg) are alternatives when IV/IM access is unavailable. A second benzodiazepine dose can be administered after 5 minutes if seizures persist.
Second-Line Therapy: The ESETT Trial
The Established Status Epilepticus Treatment Trial (ESETT, 2019, n=384) compared fosphenytoin (20 mg PE/kg IV), levetiracetam (60 mg/kg IV, max 4,500 mg), and valproate (40 mg/kg IV, max 3,000 mg) in benzodiazepine-refractory SE. Seizure cessation at 60 minutes was 45% for fosphenytoin, 47% for levetiracetam, and 46% for valproate, with no significant differences (p=0.056 for any pairwise comparison). This trial established that clinicians can choose among these three agents based on patient-specific factors: fosphenytoin avoided in cardiac arrhythmia, valproate avoided in hepatic disease and pregnancy (teratogenicity), levetiracetam preferred when drug interactions are a concern.
Sponsored
Refractory Status Epilepticus
Refractory SE (RSE), defined as seizure persistence after adequate doses of both first-line benzodiazepine and second-line antiseizure medication, occurs in 30-40% of SE cases. Management requires continuous IV anesthetics with continuous EEG monitoring: midazolam infusion (0.2 mg/kg bolus, then 0.1-2.0 mg/kg/hr), propofol (1-2 mg/kg bolus, then 20-65 mcg/kg/min, monitoring for propofol infusion syndrome with daily CK and triglycerides), or pentobarbital (5-15 mg/kg bolus, then 0.5-5 mg/kg/hr). The target is burst-suppression pattern on EEG for 24-48 hours before gradual weaning. Midazolam is generally preferred initially due to fewer hemodynamic side effects, though breakthrough seizures are more common.
Super-Refractory SE and Emerging Therapies
Super-refractory SE (SRSE), persisting for 24 or more hours despite anesthetic infusion, carries mortality of 30-50%. Ketamine infusion (1-5 mg/kg/hr) has emerged as an important adjunct, with a systematic review showing seizure cessation in 57% of SRSE cases. Allopregnanolone (brexanolone, approved for postpartum depression) has been used as a positive allosteric modulator of synaptic and extrasynaptic GABA-A receptors in SRSE, addressing the receptor trafficking that underlies benzodiazepine resistance. The ongoing STATUS trial is evaluating ketamine versus standard anesthetic therapy for RSE. Additional options for SRSE include immunotherapy (when autoimmune encephalitis is suspected), therapeutic hypothermia (32-35 degrees Celsius), ketogenic diet (inducing ketosis within 48 hours), and electroconvulsive therapy in selected cases.
Sponsored
Want to try Ailva?
Ailva is a clinical intelligence platform that delivers evidence-based answers with verified citations and cross-system reasoning. Free for all NPI holders.